Spyre Therapeutics (SYRE) Common Equity (2015 - 2026)

Spyre Therapeutics' Common Equity history runs 12 years deep, the most recent figure standing at $670.8 million for Q1 2026.

• Quarterly Common Equity rose 39.0% year-over-year to $670.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.8 million (up 39.0% YoY) and the FY2025 annual result came in at $715.2 million, up 38.13% from the prior year.
• Common Equity was $670.8 million for Q1 2026 at Spyre Therapeutics, down from $715.2 million in the prior quarter.
• Across five years, Common Equity topped out at $715.2 million in Q4 2025 and bottomed at -$245.4 million in Q3 2023.
• A 5-year average of $245.9 million and a median of $184.0 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 463.26% — and 2024, when it surged 352.48%.
• Spyre Therapeutics' Common Equity stood at $50.3 million in 2022, then surged by 265.8% to $184.0 million in 2023, then surged by 181.39% to $517.8 million in 2024, then soared by 38.13% to $715.2 million in 2025, then decreased by 6.21% to $670.8 million in 2026.
• Business Quant data shows SYRE's Common Equity at $670.8 million in Q1 2026, $715.2 million in Q4 2025, and $455.1 million in Q3 2025.